Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Open accessThe DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Fever may be the only clinical symptom at the onset of infection in neutropenic cancer patients undergoing myelosuppressive chemotherapy. A prompt and evidence-based diagnostic and therapeutic approach is mandatory. A systematic search of current literature was conducted, including only full papers and excluding allogeneic hematopoietic stem cell transplant recipients. Recommendations for diagnosis and therapy were developed by an expert panel and approved after plenary discussion by the AGIHO. Randomized clinical trials were mainly available for therapeutic decisions, and new diagnostic procedures have been introduced into clinical practice in the past decade. Stratification into a high-risk versus low-risk patient population is recommended. In high-risk patients, initial empirical antimicrobial therapy should be active against pathogens most commonly involved in microbiologically documented and most threatening infections, including Pseudomonas aeruginosa, but excluding coagulase-negative staphylococci. In patients whose expected duration of neutropenia is more than 7 days and who do not respond to first-line antibacterial treatment, specifically in the absence of mold-active antifungal prophylaxis, further therapy should be directed also against fungi, in particular Aspergillus species. With regard to antimicrobial stewardship, treatment duration after defervescence in persistently neutropenic patients must be critically reconsidered and the choice of anti-infective agents adjusted to local epidemiology. This guideline updates recommendations for diagnosis and empirical therapy of fever of unknown origin in adult neutropenic cancer patients in light of the challenges of antimicrobial stewardship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
Goossens, H., Ferech, M., Vander Stichele, R., & Elseviers, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17907-0 · Cited by 3,359 · cited 6×
“aureus (MRSA) [33] and with a higher prevalence of multidrug resistance among enterobacteria via extended-spectrum beta-lactamases (ESBL) [34, 35].”
BackgroundInfluentialFerrer, R., Martin-Loeches, I., Phillips, G., Osborn, T. M., Townsend, S., Dellinger, R. P., Artigas, A., Schorr, C., & Levy, M. M. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000330 · Cited by 1,480
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., & Lyman, G. H. (2006) · Cancer · doi:10.1002/cncr.21847 · Cited by 1,176
Klastersky, J., Paesmans, M., Rubenstein, E. B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3038 · Cited by 1,171 · cited 3×
“These individual factors can be identified by the use of the Multinational Association of Supportive Care in Cancer (MASCC) criteria [17], which have been repeatedly validated [19–21] and are shown in Table 2.”
BackgroundMethodInfluentialWalsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · cited 1×
“For voriconazole (BI), a prospective trial could not demonstrate non-inferiority to liposomal AmB in a composite endpoint, although it was associatedwith a lower rate of breakthrough fungal infections [136].”
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919 · cited 1×
“For empirical moldactive antifungal therapy in febrile neutropenic patients, caspofungin and liposomal amphotericin B (AmB) are approved [129, 130].”
BackgroundSelf-citation(2006) · PubMed · Cited by 906
Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 904 · cited 1×
“If G-CSF has not been started before the onset of neutropenia, its interventional use can be considered in patients with fever and neutropenia who are at high risk for infection-associated complications or who have prognostic factors that are predictive of poor clinical outcomes, including expected prolonged (> 10 day…”
BackgroundCombination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836 · cited 1×
“Combining antibacterial agents in this indication has also not been shown to prevent the development of resistance [95].”
BackgroundAverbuch, D., Orasch, C., Cordonnier, C., Livermore, D. M., Mikulska, M., Viscoli, C., Gyssens, I. C., Kern, W. V., Klyasova, G., Marchetti, O., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.091025 · Cited by 632 · cited 1×
“Challenges of antimicrobial stewardship in an era of globally increasing multidrug-resistance and missing development of new broad-spectrum anti-infectives gave reason for the recommendation to drastically shorten the administration of antibiotics in neutropenic patients after treatment response [146].”
BackgroundMaertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., Wilmer, A., Verhaegen, J., Boogaerts, M., & Eldere, J. V. (2005) · Clinical Infectious Diseases · doi:10.1086/496927 · Cited by 592
Detection of Bloodstream Infections in Adults: How Many Blood Cultures Are Needed?
Lee, A., Mirrett, S., Reller, L. B., & Weinstein, M. P. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01555-07 · Cited by 548
Maertens, J., Verhaegen, J., Lagrou, K., Van Eldere, J., & Boogaerts, M. (2001) · Blood · doi:10.1182/blood.v97.6.1604 · Cited by 513 · cited 1×
“For high-risk patients with an expected duration of profound neutropenia > 7 days, serial (at least twice weekly) monitoring for Aspergillus galactomannan in serum has been recommended [43, 44].”
BackgroundAntifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay
Marr, K. A., Laverdiere, M., Gugel, A., & Leisenring, W. (2005) · Clinical Infectious Diseases · doi:10.1086/429921 · Cited by 471 · cited 1×
“However, the sensitivity of these tests is strongly reduced in patients given systemic moldactive antifungals [48, 49], and false-positive results may be caused by beta-lactam antibiotics, parenteral nutrition, severe intestinal mucositis, or transfusion of blood products.”
BackgroundBlot, F., Nitenberg, G., Chachatty, E., Raynard, B., Germann, N., Antoun, S., Laplanche, A., Brun-Buisson, C., & Tancrède, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11134-0 · Cited by 438 · cited 1×
“A Bdifferential time to positivity^ of ≥ 2 h between CVC and peripheral blood cultures may indicate a CVC-related infection [57, 58] and give reason for pre-emptive treatment described in a separate guideline [59] (BIIu).”
BackgroundOptimal Testing Parameters for Blood Cultures
Cockerill, F. R., Wilson, J. W., Vetter, E. A., Goodman, K. M., Torgerson, C. A., Harmsen, W. S., Schleck, C. D., Ilstrup, D. M., Washington, J. A., & Wilson, W. R. (2004) · Clinical Infectious Diseases · doi:10.1086/421087 · Cited by 435
Cordonnier, C., Pautas, C., Maury, S., Vekhoff, A., Farhat, H., Suarez, F., Dhédin, N., Isnard, F., Ades, L., Kuhnowski, F., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597395 · Cited by 389
Elting, L. S., Rubenstein, E. B., Rolston, K. V. I., & Bodey, G. P. (1997) · Clinical Infectious Diseases · doi:10.1086/514550 · Cited by 385
Kern, W. V., Cometta, A., de Bock, R., Langenaeken, J., Paesmans, M., Zanetti, G., Calandra, T., Glauser, M. P., Crokaert, F., Klastersky, J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410502 · Cited by 370
Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis
Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354 · cited 1×
“A sensitive, validated Aspergillus PCR may also be helpful (CIII) for screening of blood samples in specific high-risk populations [47].”
BackgroundPazos, C., Pontón, J., & Palacio, A. D. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.1.299-305.2005 · Cited by 337
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Self-citationBoogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321 · cited 1×
“For itraconazole, relevant data are available for the intravenous formulation [137].”
BackgroundFluoroquinolone prescribing in the United States: 1995 to 2002
Linder, J. A., Huang, E. S., Steinman, M. A., Gonzales, R., & Stafford, R. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.09.015 · Cited by 308
Heussel, C. P., Kauczor, H.-U., Heussel, G. E., Fischer, B., Begrich, M., Mildenberger, P., & Thelen, M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.796 · Cited by 305 · cited 1×
“After ≥ 96 h of persistent or recurrent fever despite adequate therapy, a multislice pulmonary CT scan (AIIu) [10, 118, 119] should be performed (preferably within 24 h after indication), independent of respiratory symptoms (AIIu).”
BackgroundOutpatient treatment of febrile episodes in low-risk neutropenic patients with cancer
Rubenstein, E. B., Rolston, K., Escalante, C., Manzullo, E., Hughes, P., Fender, A., Elting, L., Bodey, G. P., Holmes, F., Loewy, J., et al. (1993) · Cancer · doi:10.1002/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h · Cited by 286 · cited 1×
“In the case of confirmed penicillin allergy, amoxicillin/clavulanate may be replaced by clindamycin [107] or cefuroxime axetil (BIIu) [108].”
BackgroundSurvival in neutropenic patients with severe sepsis or septic shock*
Legrand, M., Max, A., Peigne, V., Mariotte, E., Canet, E., Debrumetz, A., Lemiale, V., Seguin, A., Darmon, M., Schlemmer, B., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31822b50c2 · Cited by 281
Cometta, A., Calandra, T., Gaya, H., Zinner, S. H., de Bock, R., Del Favero, A., Bucaneve, G., Crokaert, F., Kern, W. V., Klastersky, J., et al. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1108 · Cited by 275
Efficacy and safety of cefepime: a systematic review and meta-analysis
Yahav, D., Paul, M., Fraser, A., Sarid, N., & Leibovici, L. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70109-3 · Cited by 265 · cited 1×
“1 A first meta-analysis of cefepime in this setting had indicated an excess mortality compared with other antibiotics [82]; however, after data reevaluation by the US-FDA, this was not confirmed and approval was not changed [83, 84].”
ResultSenn, L., Robinson, J. O., Schmidt, S., Knaup, M., Asahi, N., Satomura, S., Matsuura, S., Duvoisin, B., Bille, J., Calandra, T., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/527382 · Cited by 263 · cited 1×
“Monitoring patients with 1,3-beta-D-glucan in blood samples [45, 46] is being discussed as an alternative but rarely used due to higher costs.”
BackgroundNeutropenic enterocolitis in adults: systematic analysis of evidence quality
Gorschlüter, M., Mey, U., Strehl, J., Ziske, C., Schepke, M., Schmidt‐Wolf, I. G. H., Sauerbruch, T., & Glasmacher, A. (2005) · European Journal of Haematology · doi:10.1111/j.1600-0609.2005.00442.x · Cited by 262
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Self-citationAntimicrobial therapy of unexplained fever in neutropenic patients
Link, H., B�hme, A., Cornely, O. A., H�ffken, K., Kellner, O., Kern, W. V., Mahlberg, R., Maschmeyer, G., Nowrousian, M. R., Ostermann, H., et al. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0764-4 · Cited by 251
Self-citationTissari, P., Zumla, A., Tarkka, E., Mero, S., Savolainen, L., Vaara, M., Aittakorpi, A., Laakso, S., Lindfors, M., Piiparinen, H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61569-5 · Cited by 219 · cited 2×
“Multiplex PCR-based methods do not replace the standard microbiology (CIIu) [60–64] but may improve turnaround time, sensitivity, and specificity of pathogen detection [59].”
BackgroundMethodon behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation), Ullmann, A. J., Schmidt-Hieber, M., Bertz, H., Heinz, W. J., Kiehl, M., Krüger, W., Mousset, S., Neuburger, S., Neumann, S., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2711-1 · Cited by 212
Self-citationEmergence of fluoroquinolone-resistant Escherichia coli at a cancer center
Kern, W. V., Andriof, E., Oethinger, M., Kern, P., Hacker, J., & Marre, R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.681 · Cited by 193
Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT.
Heussel, C. P., Kauczor, H. U., Heussel, G., Fischer, B., Mildenberger, P., & Thelen, M. (1997) · American Journal of Roentgenology · doi:10.2214/ajr.169.5.9353456 · Cited by 192 · cited 1×
“After ≥ 96 h of persistent or recurrent fever despite adequate therapy, a multislice pulmonary CT scan (AIIu) [10, 118, 119] should be performed (preferably within 24 h after indication), independent of respiratory symptoms (AIIu).”
BackgroundPaul, M., Dickstein, Y., Schlesinger, A., Grozinsky-Glasberg, S., Soares-Weiser, K., & Leibovici, L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003038.pub2 · Cited by 177
The Role of Procalcitonin in Febrile Neutropenic Patients: Review of the Literature
Sakr, Y., Sponholz, C., Tuche, F., Brunkhorst, F., & Reinhart, K. (2008) · Infection · doi:10.1007/s15010-008-7374-y · Cited by 174
Maertens, J., Theunissen, K., Verbeken, E., Lagrou, K., Verhaegen, J., Boogaerts, M., & Eldere, J. V. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05140.x · Cited by 169 · cited 1×
“For high-risk patients with an expected duration of profound neutropenia > 7 days, serial (at least twice weekly) monitoring for Aspergillus galactomannan in serum has been recommended [43, 44].”
BackgroundCometta, A., Kern, W. V., De Bock, R., Paesmans, M., Vandenbergh, M., Crokaert, F., Engelhard, D., Marchetti, O., Akan, H., Skoutelis, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376637 · Cited by 168 · cited 1×
“The empirical addition of vancomycin after non-response to piperacillin/tazobactam [121] or teicoplanin after non-response to imipenem [123] has not been more effective than placebo, and defervescence after another 72 h of the unmodified betalactam regimen (placebo arms) was 45%.”
BackgroundCharbonneau, P., Parienti, J.-J., Thibon, P., Ramakers, M., Daubin, C., du Cheyron, D., Lebouvier, G., Le Coutour, X., Leclercq, R., & French Fluoroquinolone Free (3F) Study Group (2006) · Clinical Infectious Diseases · doi:10.1086/500319 · Cited by 166 · cited 7×
“aureus (MRSA) [33] and with a higher prevalence of multidrug resistance among enterobacteria via extended-spectrum beta-lactamases (ESBL) [34, 35].”
BackgroundInfluentialKern, W. V., Klose, K., Jellen-Ritter, A., Oethinger, M. D., Bohnert, J. A., Kern, P., Reuter, S., von Baum, H., & Marre, R. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-1278-x · Cited by 165
Averbuch, D., Cordonnier, C., Livermore, D. M., Mikulska, M., Orasch, C., Viscoli, C., Gyssens, I. C., Kern, W. V., Klyasova, G., Marchetti, O., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.091330 · Cited by 158
Furno, P., Bucaneve, G., & Favero, A. D. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00241-4 · Cited by 157
Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies
Mancini, N., Clerici, D. T., Diotti, R. A., Perotti, M., Ghidoli, N., Marco, D. D., Pizzorno, B., Emrich, T., Burioni, R., Ciceri, F., et al. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47732-0 · Cited by 154
von Lilienfeld‐Toal, M., Dietrich, M. P., Glasmacher, A. G., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1156-y · Cited by 146
Innes, H., Smith, D. B., O'Reilly, S. M., CLARK, P. I., Kelly, V., & Marshall, E. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600993 · Cited by 145 · cited 1×
“outpatient treatment after defervescence or stabilization within the first 2 days, is an alternative approach validated in clinical studies (AI) [18, 19, 104].”
MethodMaschmeyer, G., Carratalà, J., Buchheidt, D., Hamprecht, A., Heussel, C. P., Kahl, C., Lorenz, J., Neumann, S., Rieger, C., Ruhnke, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu192 · Cited by 145
Self-citationNeumann, S., Krause, S. W., Maschmeyer, G., Schiel, X., & von Lilienfeld‐Toal, M. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1698-0 · Cited by 144 · cited 1×
“Separate AGIHO guidelines for hematological and oncological patients have been published on sepsis [4], primary prophylaxis of bacterial [5] and fungal infections [6], prevention of infections after allogeneic hematopoietic stem cell transplantation (HSCT) [7], diagnosis and treatment of invasive fungal infections [8,…”
BackgroundSelf-citationRuhnke, M., Böhme, A., Buchheidt, D., Cornely, O. A., Donhuijsen, K., Einsele, H., Enzensberger, R., Hebart, H. F., Heußel, C. P., Horger, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr407 · Cited by 144 · cited 3×
“presenting in the emergency room, prompt start of antimicrobial therapy is required (AI) and immediate referral to an intensive care unit must be considered [8].”
BackgroundSelf-citationInvasive Aspergillus Rhinosinusitis in Patients with Acute Leukemia
Talbot, G. H., Huang, A., & Provencher, M. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.2.219 · Cited by 143 · cited 14×
“In the case of hematopoietic recovery to a neutrophil count of >500/μl, empirical antimicrobial therapy can be safely discontinued after 2 days of stable defervescence [22] (BIII).”
BackgroundInfluentialThe impact of penicillin skin testing on clinical practice and antimicrobial stewardship
Rimawi, R. H., Cook, P. P., Gooch, M., Kabchi, B., Ashraf, M. S., Rimawi, B. H., Gebregziabher, M., & Siraj, D. S. (2013) · Journal of Hospital Medicine · doi:10.1002/jhm.2036 · Cited by 141
Bow, E. J., Rotstein, C., Noskin, G. A., re, M. L., Schwarer, A. P., Segal, B. H., Seymour, J. F., Szer, J., & Sanche, S. E. (2006) · Clinical Infectious Diseases · doi:10.1086/505393 · Cited by 140
Liss, B., Vehreschild, J. J., Cornely, O. A., Hallek, M. J., Fätkenheuer, G., Wisplinghoff, H., Seifert, H., & Vehreschild, M. J. G. T. (2012) · Infection · doi:10.1007/s15010-012-0269-y · Cited by 139
Self-citationvon Lilienfeld-Toal, M., Lehmann, L. E., Raadts, A. D., Hahn-Ast, C., Orlopp, K. S., Marklein, G., Purr, I., Cook, G., Hoeft, A., Glasmacher, A., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00491-09 · Cited by 132
Self-citationHentrich, M., Schalk, E., Schmidt‐Hieber, M., Chaberny, I. F., Mousset, S., Buchheidt, D., Ruhnke, M., Penack, O., Salwender, H. J., Wolf, H.-H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt545 · Cited by 128
Self-citationPrat, C., Sancho, J., Domínguez, J., Xicoy, B., Giménez, M., Ferra, C. M., Blanco, S., Lacoma, A., Ribera, J., & Ausina, V. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802258956 · Cited by 125
Grillon, A., Schramm, F., Kleinberg, M., & Jehl, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156690 · Cited by 124
Kirchhoff, L. V., & Sheagren, J. N. (1985) · Infection Control · doi:10.1017/s0195941700063591 · Cited by 124
Seifert, H., Cornely, O. A., Seggewiss, K., Decker, M., Stefanik, D., Wisplinghoff, H., & Fätkenheuer, G. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.118-123.2003 · Cited by 122 · cited 1×
“A Bdifferential time to positivity^ of ≥ 2 h between CVC and peripheral blood cultures may indicate a CVC-related infection [57, 58] and give reason for pre-emptive treatment described in a separate guideline [59] (BIIu).”
BackgroundSelf-citationPenack, O., Becker, C., Buchheidt, D., Christopeit, M., Kiehl, M. G., von Lilienfeld‐Toal, M., Hentrich, M., Reinwald, M., Salwender, H. J., Schalk, E., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2086-0 · Cited by 119
Self-citationInterventional antimicrobial therapy in febrile neutropenic patients
Link, H., Maschmeyer, G., Meyer, P., Hiddemann, W., Stille, W., Helmerking, M., & D. Adam for the study group of the Paul Ehrlich Society for Chemotherapy (1994) · Annals of Hematology · doi:10.1007/bf01700277 · Cited by 119 · cited 3×
“A continuation until neutrophil recovery [143] has been questioned by results from several studies [22, 125, 144, 145] on discontinuation of parenteral antibiotics in responding, but persistently neutropenic patients, showing no substantial rates of recurrence of fever or documented infections.”
BackgroundResultSelf-citationLamoth, F., Jaton, K., Prod'hom, G., Senn, L., Bille, J., Calandra, T., & Marchetti, O. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00147-10 · Cited by 116 · cited 1×
“, doripenem [88], ceftazidimeavibactam [89], ceftolozane-tazobactam [64, 90], or cefozopran”
BackgroundVehreschild, M. J. G. T., Hamprecht, A. G., Peterson, L. R., Schubert, S., Hantschel, M., Peter, S., Schafhausen, P., Rohde, H., von Lilienfeld‐Toal, M., Bekeredjian‐Ding, I., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku305 · Cited by 112
Self-citationRuhnke, M., Arnold, R., & Gastmeier, P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70344-4 · Cited by 112
Self-citationTeuffel, O., Ethier, M. C., Alibhai, S. M. H., Beyene, J., & Sung, L. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq745 · Cited by 108 · cited 1×
“practical obstacles to outpatient management (Table 3), oral and outpatient therapy is recommended (AI) [103].”
BackgroundTacke, D., Buchheidt, D., Karthaus, M., Krause, S. W., Maschmeyer, G., Neumann, S., Ostermann, H., Penack, O., Rieger, C. T., Ruhnke, M., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2108-y · Cited by 105 · cited 1×
“Separate AGIHO guidelines for hematological and oncological patients have been published on sepsis [4], primary prophylaxis of bacterial [5] and fungal infections [6], prevention of infections after allogeneic hematopoietic stem cell transplantation (HSCT) [7], diagnosis and treatment of invasive fungal infections [8,…”
BackgroundSelf-citationVardakas, K. Z., Samonis, G., Chrysanthopoulou, S. A., Bliziotis, I. A., & Falagas, M. E. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70164-x · Cited by 104 · cited 1×
“A combination therapy including vancomycin or teicoplanin (DIIr) or linezolid (DIII) is generally discouraged for empirical first-line therapy [100] but might be considered in the case of (CIII) severe mucositis, skin or soft tissue infection, foreign body infection, or documented colonization of a patient with MRSA.”
BackgroundTime to antibiotics and outcomes in cancer patients with febrile neutropenia
Perron, T., Emara, M. R., & Ahmed, S. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-162 · Cited by 101
Kern, W. V., Marchetti, O., Drgoňa, Ľ., Akan, H., Aoun, M., Akova, M., Bock, R. D., Paesmans, M., Viscoli, C., & Calandra, T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8109 · Cited by 96
von Lilienfeld‐Toal, M., Berger, A., Christopeit, M., Hentrich, M., Heußel, C. P., Kalkreuth, J., Klein, M., Kochanek, M., Penack, O., Hauf, E., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.015 · Cited by 95 · cited 1×
“infections after autologous HSCT [14], and community respiratory viral infections [15].”
BackgroundSelf-citationGirmenia, C., Micozzi, A., Gentile, G., Santilli, S., Arleo, E., Cardarelli, L., Capria, S., Minotti, C., Cartoni, C., Brocchieri, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8032 · Cited by 93
Reinwald, M., Hummel, M., Kovalevskaya, E., Spiess, B., Heinz, W. J., Vehreschild, J. J., Schultheis, B., Krause, S. W., Claus, B., Suedhoff, T., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks208 · Cited by 92 · cited 1×
“However, the sensitivity of these tests is strongly reduced in patients given systemic moldactive antifungals [48, 49], and false-positive results may be caused by beta-lactam antibiotics, parenteral nutrition, severe intestinal mucositis, or transfusion of blood products.”
BackgroundSelf-citationSchmidt‐Hieber, M., Silling, G., Schalk, E., Heinz, W., Panse, J., Penack, O., Christopeit, M., Buchheidt, D., Meyding‐Lamadé, U., Hähnel, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw155 · Cited by 92
Self-citationPaul, M., Yahav, D., Bivas, A., Fraser, A., & Leibovici, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005197.pub3 · Cited by 89
Meta‐Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use
Kim, P. W., Wu, Y., Cooper, C. K., Rochester, G., Valappil, T., Wang, Y., Kornegay, C. J., & Nambiar, S. (2010) · Clinical Infectious Diseases · doi:10.1086/655131 · Cited by 89 · cited 1×
“1 A first meta-analysis of cefepime in this setting had indicated an excess mortality compared with other antibiotics [82]; however, after data reevaluation by the US-FDA, this was not confirmed and approval was not changed [83, 84].”
ResultWisplinghoff, H., Cornely, O. A., Moser, S., Bethe, U., Stützer, H., Salzberger, B., Fätkenheuer, G., & Seifert, H. (2003) · Infection Control and Hospital Epidemiology · doi:10.1086/502158 · Cited by 88
Self-citationWu, C. W., Wu, J. Y., Chen, C.-K., Huang, S. L., Hsu, S.-C., Lee, M.-T. G., Chang, S. S., & Lee, C. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2650-8 · Cited by 86
Clinical implications of β-lactam–aminoglycoside synergism: systematic review of randomised trials
Marcus, R., Paul, M., Elphick, H., & Leibovici, L. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.029 · Cited by 84
de Bont, E. S. J. M., Vellenga, E., Swaanenburg, J. C. J. M., Fidler, V., Visser, P., & Kamps, W. A. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01707.x · Cited by 84
Goldberg, E., Gafter‐Gvili, A., Robenshtok, E., Leibovici, L., & Paul, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.040 · Cited by 81
Cherif, H., Johansson, E., Björkholm, M., & Kalin, M. (2006) · PubMed · Cited by 78
Bucaneve, G., Micozzi, A., Picardi, M., Ballanti, S., Cascavilla, N., Salutari, P., Specchia, G., Fanci, R., Luppi, M., Cudillo, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.6963 · Cited by 76
Secmeer, G., Devrim, İ., Kara, A., Ceyhan, M., Cengiz, B., Kutluk, T., Büyükpamukçu, M., Yetgin, S., Tuncer, M. A., Uludag, A. K., et al. (2007) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3180320b5b · Cited by 72
Erjavec, Z., de Vries-Hospers, H. G., Laseur, M., Halie, R. M., & Daenen, S. M. G. J. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.6.843 · Cited by 70
Kubiak, D. W., Porter, J., McDonnell, A., Delgado-Flores, J. O., Mui, E., Baden, L. R., & Marty, F. M. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.005 · Cited by 68
Guembe, M., Rodríguez‐Créixems, M., Sánchez‐Carrillo, C., Pérez‐Parra, A., Martín‐Rabadán, P., & Bouza, E. (2010) · Clinical Infectious Diseases · doi:10.1086/652766 · Cited by 65
Persson, L. A., Söderquist, B., Engervall, P., Vikerfors, T., Hansson, L., & Tidefelt, U. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00387.x · Cited by 64
Bossaer, J. B., Hall, P. D., & Garrett-Mayer, E. S. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0808-y · Cited by 64 · cited 7×
“Although a higher rate of VRE infections has been found in VRE-colonized patients [31, 32, 101], the addition of linezolid to empirical first-line treatment has not shown a significant benefit [102].”
BackgroundInfluentialWeißinger, F., Auner, H. W., Bertz, H., Buchheidt, D., Cornely, O. A., Egerer, G., Heinz, W., Karthaus, M., Kiehl, M. G., Krüger, W., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1456-8 · Cited by 61 · cited 3×
“infections after autologous HSCT [14], and community respiratory viral infections [15].”
BackgroundSelf-citationPaul, M., Schlesinger, A., Grozinsky‐Glasberg, S., Soares‐Weiser, K., & Leibovici, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003038 · Cited by 60
Tan, B. H., Low, J. G. H., Chlebicka, N. L., Kurup, A., Cheah, F. K., Lin, R. T. P., Goh, Y. T., & Wong, G. C. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.01.011 · Cited by 58
Robinson, J. O., Lamoth, F., Bally, F., Knaup, M., Calandra, T., & Marchetti, O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018886 · Cited by 57 · cited 1×
“Also, monitoring of procalcitonin on day 2 after onset of fever may help to detect a minority of patients with potentially severe infections, and in the case of persistent fever, it may contribute to early diagnosis of invasive mycoses [113].”
BackgroundVos, F. J., Donnelly, J. P., Oyen, W. J. G., Kullberg, B. J., Bleeker‐Rovers, C. P., & Blijlevens, N. M. A. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1939-1 · Cited by 52
Penicillin skin testing as an antimicrobial stewardship initiative
Jones, B. M., & Bland, C. M. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160233 · Cited by 48
Schiel, X., Link, H., Maschmeyer, G., Glaß, B., Cornely, O. A., Buchheidt, D., Wilhelm, M., Silling, G., Helmerking, M., Hiddemann, W., et al. (2006) · Infection · doi:10.1007/s15010-006-5113-9 · Cited by 46
Self-citationRAAD, I. I., Whimbey, E. E., Rolston, K. V., Abi-Said, D., Hachem, R. Y., Pandya, R. G., Ghaddar, H. M., Karl, C. L., & Bodey, G. P. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1386::aid-cncr25>3.0.co;2-x · Cited by 46 · cited 8×
“In patients with persistent FUO in whom no focus of infection has been found, empirical removal or change of the catheter may be justified (CIII).”
BackgroundInfluentialVehreschild, M. J. G. T., Vehreschild, J. J., Hübel, K., Hentrich, M., Schmidt‐Hieber, M., Christopeit, M., Maschmeyer, G., Schalk, E., Cornely, O. A., & Neumann, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt001 · Cited by 44
Self-citationSlobbe, L., van der Waal, L., Jongman, L. R., Lugtenburg, P. J., & Rijnders, B. J. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.025 · Cited by 44
Mavros, M. N., Polyzos, K. A., Rafailidis, P. I., & Falagas, M. E. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq451 · Cited by 43 · cited 1×
“When aminoglycoside antibiotics are given, therapeutic drug monitoring is mandatory (AIIu) and once-daily dosing is appropriate (AIIr) [99].”
BackgroundNijhuis, C. S. M. O., Gietema, J. A., Vellenga, E., Daenen, S. M. G. J., de Bont, E. S. J. M., Kamps, W. A., Groen, H. J. M., van der Jagt, E. J., & van der Graaf, W. T. A. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.06.002 · Cited by 43
Yanada, M., Kiyoi, H., Murata, M., Suzuki, M., Iwai, M., Yokozawa, T., Baba, H., Emi, N., & Naoe, T. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1498 · Cited by 40
Lisboa, L. F., de Miranda, B. G., Batista, M. V., Dulley, F. L., Fonseca, G. G., Guimarães, T., Levin, A. S., Shikanai‐Yasuda, M. A., & Costa, S. F. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.02.001 · Cited by 40
Rolston, K. V. I., Frisbee‐Hume, S. E., LeBlanc, B. M., Streeter, H., & Ho, D. H. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00115-9 · Cited by 39
Cornelissen, J. J., Rozenberg-Arska, M., & Dekker, A. W. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1300 · Cited by 37 · cited 1×
“A continuation until neutrophil recovery [143] has been questioned by results from several studies [22, 125, 144, 145] on discontinuation of parenteral antibiotics in responding, but persistently neutropenic patients, showing no substantial rates of recurrence of fever or documented infections.”
ResultUse of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients
Guy, S., Tramontana, A. R., Worth, L. J., Lau, E. W. F., Hicks, R. J., Seymour, J. F., Thursky, K., & Slavin, M. A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2143-7 · Cited by 35
Saito, T., Yoshioka, S., Iinuma, Y., Takakura, S., Fujihara, N., Ichinohe, T., Ishikawa, T., Uchiyama, T., & Ichiyama, S. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0428-8 · Cited by 34 · cited 1×
“After ciprofloxacin prophylaxis, a relative predominance of infections caused by gram-positive cocci compared with gram-negative bacteria has been observed [30].”
BackgroundPenicillin Allergy Testing: A Key Component of Antibiotic Stewardship
Macy, E. M., Khan, D. A., Castells, M., & Lang, D. M. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw795 · Cited by 31
Toubai, T., Tanaka, J., Ota, S., Shigematsu, A., Shono, Y., Ibata, M., Hashino, S., Kondo, T., Kakinoki, Y., Masauzi, N., et al. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6021 · Cited by 31
Desmet, S., Maertens, J. A., Bueselinck, K., & Lagrou, K. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.01066-16 · Cited by 28
Empirical antifungal therapy in selected patients with persistent febrile neutropenia
Aguilar‐Guisado, M., Espigado, I., Cordero, E., Noguer, M., Parody, R., Pachón, J., & Cisneros, J. M. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.125 · Cited by 27
Guido, M., Quattrocchi, M. R., Zizza, A., Pasanisi, G., Pavone, V., Lobreglio, G., Gabutti, G., & De Donno, M. A. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2012.53.2.326 · Cited by 27
Jeong, S. H., Kim, D. Y., Jang, J. H., Mun, Y., Choi, C. W., Kim, S., Kim, J. S., & Park, J. S. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2545-2 · Cited by 27
Gafter‐Gvili, A., Paul, M., Bernstine, H., Vidal, L., Ram, R., Raanani, P., Yeshurun, M., Tadmor, B., Leibovici, L., Shpilberg, O., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.06.025 · Cited by 22
on behalf of the IDEA study investigators, Maschmeyer, G., Heinz, W., Hertenstein, B., Horst, H. A., Requadt, C., Wagner, T., Cornely, O. A., Löffler, J., & Ruhnke, M. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1794-4 · Cited by 21
Self-citationCytokine concentrations are not predictive of bacteremia in febrile neutropenic patients
Büyükberber, N., Buyukberber, S., Sevinç, A., & Camcı, C. (2008) · Medical Oncology · doi:10.1007/s12032-008-9081-z · Cited by 20
Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy
Nakagawa, Y., Suzuki, K., & Masaoka, T. (2009) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-009-0683-y · Cited by 16
Ng, E., Liew, Y., Koh, L. P., & Hsu, L. Y. (2010) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(10)60102-7 · Cited by 15 · cited 1×
“As a consequence, the use of quinolones for interventional treatment in febrile neutropenic patients should be limited to microbiologically documented infections caused by in vitro susceptible microorganisms [39].”
Background¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.
Camus, V., Edet‐Sanson, A., Bubenheim, M., et al. (2015) · PubMed · Cited by 14
van Vliet, M., Potting, C. M. J., Sturm, P., Donnelly, J. P., & Blijlevens, N. M. A. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01264.x · Cited by 14 · cited 1×
“Emergency treatment algorithms for this clinical situation as well as supervision or audits have been shown to improve timely and adequate therapy [81].”
BackgroundPre-emptive diagnosis and treatment of fungal infections—evaluation of a single-centre policy
Schneider, T., Halter, J. P., Heim, D. A., Passweg, J. R., Stern, M., Tichelli, A., Weisser, M., & Gerull, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03589.x · Cited by 12
Nesher, L., Tverdek, F. P., Mahajan, S. N., Chemaly, R. F., & Rolston, K. V. I. (2015) · Infection · doi:10.1007/s15010-015-0784-8 · Cited by 9
Sipsas, N. V., Kosmas, C., Ziakas, P. D., Karabelis, A., Vadiaka, M., Skopelitis, E. E., Kordossis, T., & Tsavaris, N. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701367769 · Cited by 7 · cited 1×
“In the case of confirmed penicillin allergy, amoxicillin/clavulanate may be replaced by clindamycin [107] or cefuroxime axetil (BIIu) [108].”
BackgroundToya, T., Nannya, Y., Narukawa, K., Ichikawa, M., & Kurokawa, M. (2012) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.65.228 · Cited by 6 · cited 1×
“, doripenem [88], ceftazidimeavibactam [89], ceftolozane-tazobactam [64, 90], or cefozopran”
Background
Cited by
(2021) · doi:10.3322/caac.21697 · Cited by 201
Cornely, O. A., Koehler, P., Arenz, D., & C. Mellinghoff, S. (2018) · Mycoses · doi:10.1111/myc.12820 · Cited by 55
Self-citation
Metadata
- Authors
- Heinz, W. J., Buchheidt, D., Christopeit, M., von Lilienfeld-Toal, M., Cornely, O. A., Einsele, H., Karthaus, M., Link, H., Mahlberg, R., Neumann, S., Ostermann, H., Penack, O., Ruhnke, M., Sandherr, M., Schiel, X., Vehreschild, J. J., Weissinger, F., & Maschmeyer, G.
- Venue
- Annals of Hematology
- Published
- 2017-08-30
- Volume
- 96
- Issue
- 11
- Pages
- 1775-1792
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- OpenAlex
- W2753152241
- Cited by
- 172
- References
- 128
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.